This whitepaper provides an in-depth analysis of the patent landscape in fields of MASH (Metabolic-Associated Steatohepatitis) biomarkers and Point of Care (PoC) kits. By examining key patent applications and identifying the leading players in the field, this paper offers valuable insights into the technological advancements, competitive dynamics, and potential opportunities within this space.
Introduction
The fields of MASH (Metabolic-Associated Steatohepatitis) biomarkers and Point of Care (PoC) kits for MASH diagnostics are experiencing rapid growth and innovation. This surge is driven by the recent Rezdiffra approval and the increasing demand from physicians to detect and monitor treatment responses to the first approved MASH drug. This growth is further reflected in the consistent patenting activity, signifying intense research and development efforts by biotechnology and pharmaceutical companies, academic institutions, and healthcare technology firms.
Read full report here or download PDF below.
